knowledge -WSS

knowledge

author：fashion 2025-09-29 00:38:30 - browse：78936

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Study links childhood stress with decline in older age

knowledge

focus

WSS

Retired US general questions alleged Putin, Prigozhin meeting

It costs an awful lot of money to give away a kidney

Charles Manson follower Leslie Van Houten released from prison after 53 years

New research casts further doubt on a common procedure used with IVF

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

It costs an awful lot of money to give away a kidney

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Cancer drug shortages should be causing more outrage

The cancer stories no one wants to hear

Virginia high school admissions case could be legal follow

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

What does generative AI mean for health care? We asked experts

How the political right came to back psychedelics to treat trauma

Affirmative action in medical school literally saved lives

Flint parents haunted by uncertainty, fears of lead poisoning

Heart attack and stroke risk calculators need revising

The a glaring gap in research on serious mental illness and primary care

explore

When waiting feels immoral: Empathy in the emergency department

Palantir health business leans on meeting customers’ needs

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

'Null' research findings aren't empty of meaning. Let's publish them

Lecanemab for Alzheimer's is coming. Is the health system ready?

Florida officials tell state schools to teach AP Psychology 'in its entirety'

knowledge

focus

focus

leisure time